Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01110876 | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02046187 | Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma | terminated | Phase 1 / Phase 2 | 14 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM(INTERCEPT) | terminated | Phase 1 | 2 | Gary Archer Ph.D.OTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT04327011 | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 | terminated | Phase 1 | 65 | Tocagen Inc.INDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT03573986 | Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment | terminated | Phase 1 | 2 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03246113 | Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma | terminated | Phase 1 | 1 | New York State Psychiatric InstituteOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04002804 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme(Dendr2) | terminated | Phase 1 | 26 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 0 | Jul 1, 2019 | clinicaltrials |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00734526 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00895960 | Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | terminated | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT02176720 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | terminated | Phase 1 | 31 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01103375 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma | terminated | Phase 1 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00990496 | A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) | terminated | Phase 1 | 25 | Milton S. Hershey Medical CenterOTHER | 0 | May 2, 2018 | clinicaltrials |
| NCT01702792 | Derivation of Tumor Specific Hybridomas | terminated | Phase 1 | 1 | Dartmouth-Hitchcock Medical CenterOTHER | 0 | Apr 4, 2018 | clinicaltrials |
| NCT00354107 | Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Mar 14, 2018 | clinicaltrials |
| NCT02254954 | Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma | terminated | Phase 1 | 30 | ActelionINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT01339039 | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | terminated | Phase 1 | 26 | Patrick Y. Wen, MDOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT02510950 | Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 1 | Washington University School of MedicineOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01666600 | NOA-12: BIBF1120 and R-RT in Glioblastoma | terminated | Phase 1 / Phase 2 | 63 | Prof. Dr. Wolfgang WickOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01526837 | Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence | terminated | Phase 1 | 1 | Brain & Spine Surgeons of New YorkOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT02648633 | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma | terminated | Phase 1 | 4 | University of VirginiaOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01902771 | Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | terminated | Phase 1 | 1 | Edward ZigaOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00456612 | Radiosurgery for Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Deaconess Medical CenterOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01148966 | Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors | terminated | Phase 1 | 6 | University of WashingtonOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02025231 | Image Guided Reirradiation of High-grade Glioma | terminated | Phase 1 / Phase 2 | 31 | Rigshospitalet, DenmarkOTHER | 2 | Feb 8, 2017 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT02031965 | Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery | terminated | Phase 1 | 2 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | May 30, 2016 | clinicaltrials |
| NCT01499251 | Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma | terminated | Phase 1 | 75 | ActelionINDUSTRY | 1 | May 5, 2016 | clinicaltrials |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | terminated | Phase 1 / Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Dec 14, 2015 | clinicaltrials |
| NCT01122888 | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme | terminated | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT01378481 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT01403285 | Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma | terminated | Phase 1 | 6 | Immatics Biotechnologies GmbHINDUSTRY | 1 | May 19, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme(COGLI) | terminated | Phase 1 / Phase 2 | 2 | Baylor College of MedicineOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | terminated | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00650949 | Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma | terminated | Phase 1 / Phase 2 | 20 | Gilead SciencesINDUSTRY | 1 | May 3, 2013 | clinicaltrials |
| NCT00959946 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | PfizerINDUSTRY | 6 | Feb 22, 2013 | clinicaltrials |
| NCT01269411 | RO4929097 in Treating Patients With Recurrent Invasive Gliomas | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00005856 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2021source: clinicaltrials